Alnylam Pharmaceuticals has announced a $250 million investment to expand its manufacturing facility in Massachusetts. The ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Ketamine's rapid antidepressant effects have led to a significant increase in off-label psychiatric use, despite the lack of ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America ...

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

A. Douglas Bender is an associate professor of management in the School of Business Management of Widener University, Chester, PA, where he teaches graduate courses in managed care organizations and ...